Medifast
MED
186 hedge funds and large institutions have $440M invested in Medifast in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 60 increasing their positions, 67 reducing their positions, and 55 closing their positions.
7.85% more ownership
Funds ownership: 97.46% → 105.31% (+7.9%)
10% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 67
14% less funds holding
Funds holding: 216 → 186 (-30)
29% less call options, than puts
Call options by funds: $13.7M | Put options by funds: $19.4M
39% less capital invested
Capital invested by funds: $717M → $440M (-$277M)
55% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 55
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$35.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$22.4M |
| 3 |
Millennium Management
New York
|
+$12.5M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$5.92M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$5.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$16.5M |
| 3 |
Morgan Stanley
New York
|
-$5.46M |
| 4 |
RAG
RIA Advisory Group
Des Moines,
Iowa
|
-$5.02M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$4.78M |
MED Hedge Fund Activity: Q1 2024 in Review
186 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Medifast (MED) for Q1 2024, worth a combined $440M — down 39% from $717M a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of MED and 25 opened new positions — a net loss of 30 holders — while 67 trimmed existing stakes and 60 added.
The largest buyer was Pacer Advisors, adding an estimated $35.7M. The largest seller was Vanguard Group, cutting an estimated $22M.
- 186 institutional investors held Medifast (MED) as of Q1 2024, down from 216 in Q4 2023.
- Funds reported $440M of Medifast stock for Q1 2024, down 39% quarter-over-quarter.
- 25 funds opened new Medifast positions in Q1 2024 and 55 closed out, a net change of -30 holders.
- The largest Medifast buyer in Q1 2024 was Pacer Advisors, an estimated $35.7M added.
- The largest Medifast seller in Q1 2024 was Vanguard Group, an estimated $22M sold.
Based on aggregated 13F filings for Q1 2024.